229 related articles for article (PubMed ID: 28368488)
1. Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients.
van der Ree MH; Jansen L; Kruize Z; van Nuenen AC; van Dort KA; Takkenberg RB; Reesink HW; Kootstra NA
J Infect Dis; 2017 May; 215(9):1421-1429. PubMed ID: 28368488
[TBL] [Abstract][Full Text] [Related]
2. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.
Brunetto MR; Cavallone D; Oliveri F; Moriconi F; Colombatto P; Coco B; Ciccorossi P; Rastelli C; Romagnoli V; Cherubini B; Teilum MW; Blondal T; Bonino F
PLoS One; 2014; 9(10):e110782. PubMed ID: 25350115
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a.
Yang Y; Liu M; Deng Y; Guo Y; Zhang X; Xiang D; Jiang L; You Z; Wu Y; Li M; Mao Q
Virol J; 2018 Apr; 15(1):73. PubMed ID: 29685146
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon.
Hu Q; Wang Q; Zhang Y; Tao S; Zhang X; Liu X; Li X; Jiang X; Huang C; Xu W; Qi X; Chen L; Li Q; Huang Y
J Med Virol; 2021 Aug; 93(8):4939-4948. PubMed ID: 33666247
[TBL] [Abstract][Full Text] [Related]
5. The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
Ninomiya M; Kondo Y; Kimura O; Funayama R; Nagashima T; Kogure T; Morosawa T; Tanaka Y; Nakayama K; Shimosegawa T
J Viral Hepat; 2016 May; 23(5):330-9. PubMed ID: 26924666
[TBL] [Abstract][Full Text] [Related]
6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
7. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
[TBL] [Abstract][Full Text] [Related]
8. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
9. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.
Fujita K; Mimura S; Iwama H; Nakahara M; Oura K; Tadokoro T; Nomura T; Tani J; Yoneyama H; Morishita A; Oryu M; Himoto T; Nishitsuji H; Shimotohno K; Omata M; Masaki T
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30004437
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Virus-Encoded MicroRNA Controls Viral Replication.
Yang X; Li H; Sun H; Fan H; Hu Y; Liu M; Li X; Tang H
J Virol; 2017 May; 91(10):. PubMed ID: 28148795
[TBL] [Abstract][Full Text] [Related]
11. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
12. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
Charatcharoenwitthaya P; Sukeepaisarnjaroen W; Piratvisuth T; Thongsawat S; Sanpajit T; Chonprasertsuk S; Jeamsripong W; Sripariwuth E; Komolmit P; Patcharatrakul T; Boonsirichan R; Bunchorntavakul C; Tuntipanichteerakul S; Tanwandee T;
J Gastroenterol Hepatol; 2016 Nov; 31(11):1874-1881. PubMed ID: 26997582
[TBL] [Abstract][Full Text] [Related]
14. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
15. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
16. Differences in serum microRNA profiles in hepatitis B and C virus infection.
Akamatsu S; Hayes CN; Tsuge M; Miki D; Akiyama R; Abe H; Ochi H; Hiraga N; Imamura M; Takahashi S; Aikata H; Kawaoka T; Kawakami Y; Ohishi W; Chayama K
J Infect; 2015 Mar; 70(3):273-87. PubMed ID: 25452043
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs in hepatitis B virus-infected patients.
Ji F; Yang B; Peng X; Ding H; You H; Tien P
J Viral Hepat; 2011 Jul; 18(7):e242-51. PubMed ID: 21692939
[TBL] [Abstract][Full Text] [Related]
18. Identification of miRNAs associated with dendritic cell dysfunction during acute and chronic hepatitis B virus infection.
Singh AK; Rooge SB; Varshney A; Vasudevan M; Kumar M; Geffers R; Kumar V; Sarin SK
J Med Virol; 2021 Jun; 93(6):3697-3706. PubMed ID: 33107616
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
[TBL] [Abstract][Full Text] [Related]
20. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
